摘要多肽偶联药物是一种新兴的肿瘤靶向治疗药物，具有相对分子质量小、肿瘤细胞穿透性强及免疫原性低等特点，在肿瘤分子显像和靶向治疗中受到越来越高的重视。 177Lu-1，4，7，10-四氮杂环十二烷-1，4，7，10-四乙酸- D-苯丙氨酸1-酪氨酸3-苏氨酸8-奥曲肽（DOTATATE）作为最成功的多肽偶联药物，可特异性地与生长抑素受体（SSTR）相结合，实现肿瘤的肽受体放射性核素治疗。笔者就近年来有关 177Lu-DOTATATE在神经内分泌肿瘤中的治疗疗效、剂量选择及改善策略等方面的研究进展进行综述，为SSTR过表达肿瘤的靶向治疗提供参考。

abstractsPolypeptide drug conjugate are an emerging tumor-targeted therapy drug with the characteristics of small molecular weight, strong tumor cell penetration, and low immunogenicity, which has received increasing attention in molecular imaging and targeted therapy of tumors. 177Lu-1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid- D-Phe1-Tyr3-Thr8-octreotide (DOTATATE), as the most successful polypeptide drug conjugate, can specifically bind to the somatostatin receptor (SSTR) to achieve peptide receptor radionuclide therapy for tumors. The author reviews the research progress on the therapeutic efficacy, dose selection, and improvement strategies of 177Lu-DOTATATE in neuroendocrine neoplasms, to provide a reference for the targated therapy of SSTR overexpression tumors.